VIATRIS INC. Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent
VIATRIS INC. (VTRS) reported Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent of -$800.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentBeforeTaxPortionAttributableToParent · last filed 2022-11-07
- VIATRIS INC. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2022-09-30 was -$800.00K.
- VIATRIS INC. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2022-06-30 was -$1.00M, a 600.00% decline year-over-year.
- VIATRIS INC. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2022-03-31 was -$1.70M.
- VIATRIS INC. other comprehensive income (loss), available-for-sale securities adjustment, before tax, portion attributable to parent for the quarter ending 2021-09-30 was -$100.00K.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Tax, Portion Attributable to Parent 9 month |
|---|---|---|---|
| 2022-09-30 | -$800.00K 10-Q · filed 2022-11-07 | -$1.80M derived: sum of 2 quarters · filed 2022-11-07 | -$3.50M 10-Q · filed 2022-11-07 |
| 2022-06-30 | -$1.00M 10-Q · filed 2022-08-08 | -$2.70M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | -$1.70M 10-Q · filed 2022-05-09 | ||
| 2021-09-30 | -$100.00K 10-Q · filed 2022-11-07 | $100.00K derived: sum of 2 quarters · filed 2022-11-07 | -$800.00K 10-Q · filed 2022-11-07 |
| 2021-06-30 | $200.00K 10-Q · filed 2022-08-08 | -$700.00K 10-Q · filed 2022-08-08 | |
| 2021-03-31 | -$900.00K 10-Q · filed 2022-05-09 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-08 | $600.00K derived: sum of 2 quarters · filed 2021-11-08 | $800.00K 10-Q · filed 2021-11-08 |
| 2020-06-30 | $600.00K 10-Q · filed 2021-08-09 | $800.00K 10-Q · filed 2021-08-09 | |
| 2020-03-31 | $200.00K 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |